Alesta Therapeutics, a Leiden, the Netherlands-based biotechnology firm targeted on growing transformative small molecule therapies for uncommon ailments, raised €65M in Collection A funding.
The spherical was led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Enterprise Fund, RTW Investments, RV Make investments, Thuja Capital and SSI Technique.
The corporate intends to make use of the funds to develop operations and its R&D sector.
Alesta Therapeutics is biotechnology firm dedicated to growing novel oral small molecule therapies for underserved uncommon ailments. Its lead asset, ALE1, is being developed for hypophosphatasia (HPP), a uncommon genetic dysfunction with important unmet wants. Alesta can be advancing ALE2, a candidate to deal with Charcot-Marie-Tooth (CMT) illness.
Alesta is led by:
- Ilan Ganot, Chief Govt Officer
- Matthias Van Woensel, Ph.D., Chief Scientific Officer
- Benit Maru, MBChB, Ph.D., Chief Medical Officer
Along with the CEO, Alesta’s Board of Administrators contains:
- Laura Brass, Ph.D., Novartis Enterprise Fund
- Luc Dochez, Droia Ventures
- Dan Estes, Ph.D., Frazier Life Sciences
- Janwillem Naesens, Droia Ventures
FinSMEs
08/01/2025
